|
The Romanian division of Actavis is the Group's center of excellence in the development, production and marketing of oncology generics, and a leader in strengthening the hospital business.
Actavis has about 340 employees in Romania.
The Company holds more than 230 marketing authorisations for oncology products in Europe, Japan and the US. Over 300 dossiers for MAs are pending approval for USA, Japan and other Asian countries, the EU and various other European countries.
Oncological products made in Romania are present on markets including the US and Japan, UK, France, Germany, Austria, Switzerland, Russia, Poland and many others.
MHRA, FDA & PMDA approved
The production facility in Bucharest was approved in 2004 by the MHRA for sales in the European Union. In early 2007, a successful FDA inspection laid grounds for the Company's products to be registered on the US market, followed by the positive result of the inspection by the Japanese authority - PMDA (Pharmaceutical and Medical Devices Agency) - which took place in November 2008.
In March 2008, the oncology injectable Irinotecan Hydrochloride was launched in the US, the world's most competitive market. Irinotecan was Actavis’ first oncology product in the US.
Contact information:
Actavis in Romania
179-185 Odăii Street
Bucharest 1, 013604
Romania
Tel.: +4021 351 45 67
Fax: +4021 351 45 65
Sindan Pharma (Actavis operations)
11 Ion Mihalache Blvd.
Bucharest 1, 011171
Romania
Tel.: +4021 318 17 67
Fax: +4021 312 44 99
Managing Director: Bogdan Oghină
Email: inforo@actavis.com
Romanian local website: www.actavis.com.ro |